Dopaminergic transmission as the mechanism of action of STN-DBS

被引：0
|
作者：
Avecillas-Chasin, Josue M. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE 68198 USA
来源：
JOURNAL OF NEUROSURGERY | 2022年 / 138卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：295 / 296
页数：2
相关论文
共 50 条
  • [1] Dopaminergic transmission as the mechanism of action of STN-DBS
    Avecillas-Chasin, Josue M.
    JOURNAL OF NEUROSURGERY, 2023, 138 (01) : 295 - 296
  • [2] Dopaminergic transmission as the mechanism of action of STN-DBS Response
    Nozaki, Takao
    JOURNAL OF NEUROSURGERY, 2022, 138 (01) : 296 - 296
  • [3] Dopaminergic transmission as the mechanism of action of STN-DBS Response
    Nozaki, Takao
    JOURNAL OF NEUROSURGERY, 2023, 138 (01) : 296 - 296
  • [4] STN-DBS AND IMPULSIVITY
    Alusi, S. H.
    Osman-Farah, J.
    Vajramani, G.
    Steiger, M. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (11):
  • [5] Differential Spatiotemporal Gait Effects with Frequency and Dopaminergic Modulation in STN-DBS
    Ramdhani, R.
    Watts, J.
    Klein, M.
    Fitzpatrick, T.
    Niethammer, M.
    Khojandi, A.
    MOVEMENT DISORDERS, 2023, 38 : S764 - S765
  • [6] Differential spatiotemporal gait effects with frequency and dopaminergic modulation in STN-DBS
    Ramdhani, Ritesh A.
    Watts, Jeremy
    Kline, Myriam
    Fitzpatrick, Toni
    Niethammer, Martin
    Khojandi, Anahita
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [7] Global inhibitory control in PD is impaired ON dopaminergic medication but not ON STN-DBS
    Kuebler, D.
    Schroll, H.
    Kuehn, A.
    MOVEMENT DISORDERS, 2017, 32
  • [8] Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS
    Onder, Halil
    Comoglu, Selcuk
    JOURNAL OF NEURAL TRANSMISSION, 2024, 131 (08) : 931 - 940
  • [9] Does STN-DBS for PD increases suicidality? A meta-analysis of STN-DBS clinical trials
    Teodoro, T.
    Nzwalo, H.
    Guedes, L.
    Coelho, M.
    Rosa, M. M.
    Ferreira, J. J.
    MOVEMENT DISORDERS, 2014, 29 : S454 - S454
  • [10] Could the rate of dopaminergic medications reduction affect outcome after STN-DBS?
    Hammersley, B.
    Ellis, R.
    Bonello, M.
    Randall, A.
    Somerset, J.
    Panicker, J.
    Damodaran, D.
    Byrne, P.
    Farah, J.
    Eldridge, P.
    Alusi, S.
    MOVEMENT DISORDERS, 2018, 33 : S260 - S260
12345